APP and Alzheimer disease: The underlying mechanism has been intensively investigated by assay against the APP/PS1 mice with 5HT2AR knockdown selectively in the brain treated by adeno‐associated virus (AAV)‐ePHP‐si‐5HT2AR. Our work has strongly supported that 5HT2AR antagonism is a promising therapeutic strategy for AD and highlighted the potential of DLT in the treatment of this disease.